FIGURE 2. HSG4112 dose-dependently reduces body weight and fully normalizes obesity-related parameters in HFD-mice. (A) HSG4112 at doses 10, 30, and 100 mg·kg-1 was orally administered to HFD-mice for 6 weeks (n = 10 per group). *P < 0.05, ***P< 0.001 vs. Vehicle group; two-way ANOVA with Tukey’s multiple comparison test. (B) Representative image of mice from Normal group, Vehicle group, and HSG4112-100 mg·kg-1 group. (C) Representative image of WAT (periepididymal) and their histological section stained with H&E. Standard bar = 100µm. (D) Quantification of absolute periepididymal tissue mass. (E) Periepididymal tissue mass in percentage relative to each group’s body weight. (F) Individual white adipocyte size distribution and its mean. (G) Relative weight of perirenal fat and (H) gastrocnemius muscle. (I-K) Serum concentration of (I) leptin and (J) insulin, and (K) glucose. (L) HOMA-IR index.###P <0.001 vs. Normal group, ***P < 0.001 vs. Vehicle group; one-way ANOVA with Tukey’s multiple comparison test. No statistically significant difference observed for all comparisons of HSG4112 group vs. Normal group. All data represent terminal values of mean ± SEM.